Differential protective activities of site specific lipoxygenase inhibitors in endotoxic shock and production of tumor necrosis factor
- 1 January 1991
- journal article
- Published by Elsevier in International Journal of Immunopharmacology
- Vol. 13 (5) , 565-571
- https://doi.org/10.1016/0192-0561(91)90077-k
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Leukotrienes do not regulate interleukin 1 production by activated macrophagesBiochemical and Biophysical Research Communications, 1990
- L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitorCanadian Journal of Physiology and Pharmacology, 1989
- Lipoxygenase inhibitors suppress formation of tumor necrosis factor in, vitro and in, vivoBiochemical and Biophysical Research Communications, 1989
- TUMOR NECROSIS, CACHEXIA, SHOCK, AND INFLAMMATION: A COMMON MEDIATORAnnual Review of Biochemistry, 1988
- Increased 13-hydroxyoctadecadienoic acid content in lipopolysaccharide stimulated macrophagesBiochemical and Biophysical Research Communications, 1987
- A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytesJournal of Immunological Methods, 1986
- Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of EndotoxinScience, 1985
- AUTONOMIC PHARMACOLOGY OF LEUKOTRIENESJournal of Autonomic Pharmacology, 1985
- Production of peptide leukotrienes in endotoxin shockFEBS Letters, 1985
- The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin-1)International Journal of Immunopharmacology, 1984